Suppr超能文献

脂蛋白(a)通过α2-抗纤溶酶促进纤溶抑制。

Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

作者信息

Edelberg J M, Pizzo S V

机构信息

Department of Pathology, Duke University Medical Center, Durham, NC 27710.

出版信息

Biochem J. 1992 Aug 15;286 ( Pt 1)(Pt 1):79-84. doi: 10.1042/bj2860079.

Abstract

Plasmin inhibition by alpha 2-antiplasmin (alpha 2AP) is regulated by the vascular components fibrin(ogen) fragments, plasminogen and lipoprotein (a). Kinetic analysis demonstrates that CNBr-derived fibrinogen fragments completely protect plasmin from alpha 2AP. Plasminogen and 6-aminohexanoic acid decrease the rate of inhibition by 5- and 10-fold respectively. These studies show that CNBr-derived fibrinogen fragments and 6-aminohexanoic acid bind plasmin kringle(s) with binding constants of 2 micrograms/ml and 120 microM respectively, and that plasminogen binds to alpha 2AP with an affinity of 0.5 nM. The unmodulated inhibition is not effected by the presence of lipoprotein (a), but in the presence of protective CNBr-derived fibrinogen fragments the rate of inhibition is increased by the presence of the lipoprotein. The kinetics demonstrate that lipoprotein (a) binds to CNBr-derived fibrinogen fragments with an affinity of 4 nM, displacing plasmin from the protective surface. In addition, tissue-type plasminogen activator and trypsin inhibition by alpha 2AP is not slowed by the presence of CNBr-derived fibrinogen fragments or plasminogen (Pg), respectively. These kinetics suggest that the initial reversible interaction between plasmin and alpha 2AP is mediated by binding of the inhibitor to the kringle 1 domain of plasmin, with a reversible inhibition constant (Ki) of 5.0 x 10(-10) M. Under conditions where this kringle-inhibitor interaction is blocked, the reversible inhibition still occurs between the plasmin and alpha 2AP, but the initial Ki is increased to 5.0 x 10(-9) M. These data suggest that, in the circulation, plasmin inhibition by alpha 2AP may be down-regulated by fibrin, fibrin(ogen) fragments and Pg, but up-regulated by lipoprotein (a) in the presence of fibrin or fibrin(ogen) fragments. The lipoprotein (a)-mediated promotion of plasmin inhibition may provide an additional mechanism by which the lipoprotein impairs fibrinolysis and promotes atherosclerosis.

摘要

α2-抗纤溶酶(α2AP)对纤溶酶的抑制作用受血管成分纤维蛋白(原)片段、纤溶酶原和脂蛋白(a)的调节。动力学分析表明,溴化氰衍生的纤维蛋白原片段能完全保护纤溶酶不被α2AP抑制。纤溶酶原和6-氨基己酸分别使抑制速率降低5倍和10倍。这些研究表明,溴化氰衍生的纤维蛋白原片段和6-氨基己酸分别以2微克/毫升和120微摩尔的结合常数与纤溶酶kringle结构域结合,且纤溶酶原以0.5纳摩尔的亲和力与α2AP结合。未受调节的抑制作用不受脂蛋白(a)存在的影响,但在存在保护性溴化氰衍生的纤维蛋白原片段的情况下,脂蛋白(a)的存在会增加抑制速率。动力学表明,脂蛋白(a)以4纳摩尔的亲和力与溴化氰衍生的纤维蛋白原片段结合,将纤溶酶从保护表面置换下来。此外,组织型纤溶酶原激活剂和胰蛋白酶被α2AP抑制的作用分别不会因溴化氰衍生的纤维蛋白原片段或纤溶酶原(Pg)的存在而减慢。这些动力学表明,纤溶酶与α2AP之间最初的可逆相互作用是由抑制剂与纤溶酶kringle 1结构域的结合介导的,可逆抑制常数(Ki)为5.0×10⁻¹⁰摩尔。在这种kringle-抑制剂相互作用被阻断的条件下,纤溶酶与α2AP之间仍会发生可逆抑制,但初始Ki增加到5.0×10⁻⁹摩尔。这些数据表明,在循环中,α2AP对纤溶酶的抑制作用可能会被纤维蛋白、纤维蛋白(原)片段和Pg下调,但在存在纤维蛋白或纤维蛋白(原)片段的情况下会被脂蛋白(a)上调。脂蛋白(a)介导的纤溶酶抑制作用增强可能提供了一种额外的机制,通过该机制脂蛋白损害纤维蛋白溶解并促进动脉粥样硬化。

相似文献

本文引用的文献

8
Human plasma proteinase inhibitors.人血浆蛋白酶抑制剂
Annu Rev Biochem. 1983;52:655-709. doi: 10.1146/annurev.bi.52.070183.003255.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验